GLP-1 therapies work by helping regulate appetite, improve fullness, and support consistent fat loss
Ozempic and Wegovy have different names, dosages, and indications, but are identical in terms of their molecular makeup known as the generic medication semaglutide and both are manufactured by Novo Nordisk
Patients were either treated once weekly with semaglutide 2.4 mg or a placebo for one year
It has the strongest research backing, works through multiple biological pathways including Wnt signalling activation, collagen synthesis, and anti-inflammatory action and is available in both topical and injectable forms
Elexacaftor/tezacaftor/ivacaftor (Trikafta/Kaftrio) is approved for patients 2 years with at least one F508del allele, achieving sustained FEV1 improvement and dramatic reduction in exacerbations